Study title: Phase Ib/II Study of Selinexor in Combination with Carfilzomib, subcutaneous Isatuximab administered via investigational device, and Dexamethasone (SCID) for Patients with Relapsed and/or Relapsed Refractory Multiple Myeloma

• Open to Accrual at:
  • University of Wisconsin Carbone Cancer Center
• Learn more
  • clinicaltrials.gov: NCT07479979

Study Contact: studies@hoosiercancer.org; 317-921-2050